RHÖN-KLINIKUM Aktiengesellschaft
ISIN: DE0007042301
WKN: 704230
07 Mai 2026 08:42PM

EQS-News: RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026

RHÖN-KLINIKUM Aktiengesellschaft · ISIN: DE0007042301 · EQS - Company News
Land: Deutschland · Primärmarkt: Deutschland · EQS News ID: 2323556

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Quarter Results/Miscellaneous
RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026

07.05.2026 / 20:42 CET/CEST
The issuer is solely responsible for the content of this announcement.


CORPORATE NEWS

First quarter of 2026

RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026
 

  • Group optimises outpatient and inpatient care structures
  • Number of patients treated increased by 7.4 %, while the reported consolidated revenue is at EUR 436.1 million
  • Current financial year affected by upcoming reforms

Bad Neustadt, 7 May 2026 – RHÖN-KLINIKUM AG entered financial year 2026 with stable business performance. Consolidated revenue of EUR 436.1 million was slightly above the prior year's figure (Q1 2025: EUR 414.7 million), while EBITDA amounted to EUR 30.2 million (Q1 2025: EUR 22.6 million). Net income totalled EUR 13.1 million (Q1 2025: EUR 7.3 million). From January to March, the Group's clinics and medical centres treated 258,027 patients on an inpatient and outpatient basis, an increase of 7.4 % (Q1 2025: 240,137).

The hospital sites of the company continue to see dynamic growth. In addition to the major investments in state-of-the-art medical technology planned at all hospital sites in 2026, we are further expanding our medical and therapeutic care for patients throughout the Group.

In the first quarter of 2026, the operating business of Ortho Centrum Saale MVZ GmbH was integrated into the Group and its results included in the consolidated financial statements. The company, with six doctor’s practices in the specialist fields of orthopaedics, trauma surgery, surgery, sports medicine, sports trauma medicine and neurosurgery, was acquired to strengthen the RHÖN-Campus concept in Bad Neustadt as well as growth prospects in the clinical and outpatient sector in the region of Rhön-Grabfeld.

Outlook for 2026

For the coming financial year, we expect revenues of EUR 1.7 billion within
a range of plus or minus 5 %. For earnings before interest, tax and depreciation/amortisation (EBITDA), we expect a level of between
EUR 110 million and EUR 125 million. In addition to the financial performance indicators, we also take account of the non-financial performance indicators
of number of cases and cost weights in the management of the company and expect these to show a moderate improvement over the previous year.

The current financial year is expected to be significantly affected by legislative procedures and its corresponding substantial uncertainties. In particular, the Hospital Reform Adjustment Act (KHAG), which entered into force on 15 April 2026, as well as the implications of the Statutory Health Insurance Financial Stabilization Act (GKV-Finanzstabilisierungsgesetz), while aiming to further strengthen quality and efficiency within the healthcare system, simultaneously increase financial pressure on hospitals in the short term.

The Group’s forecast is therefore subject to considerable uncertainties. The cumulative impact of ongoing regulatory interventions, the implementation of the German hospital reform, and potential further adjustments by the legislature can currently not be reliably estimated. In addition to these developments global crises and economic pressures, which manifest – among other developments – in price increases, supply restrictions, and volatile operating conditions.

Considering these aspects, it will be decisive whether further adjustments to the ongoing reforms and supporting measures will be implemented to enable hospitals providing economically sustainable and high-quality patient care in the future.

Dr. Stefan Stranz, Member of the Executive Board of RHÖN-KLINIKUM AG: “Reliable medical care requires economically stable hospitals. Particularly against the backdrop of current reforms, it will be crucial whether financing and regulatory frameworks continue to enable hospitals to fulfill their mandate providing care in a sustainable manner.”

Dr. Gunther K. Weiß, Member of the Executive Board RHÖN-KLINIKUM AG: “Our business processes are both efficient and flexible. The close and trustworthy collaboration within the ASKLEPIOS Group plays a significant role in these. At the same time, the impact of current reforms and further regulatory interventions remains subject to considerable uncertainty. To permanently ensure high-quality and reliable patient care, hospitals require stable economic and political conditions.”

The Quarterly Statement – Q1 2026 – is published in the Internet.

CONTACT

RHÖN-KLINIKUM AG | Head of Group Finance
Norman Dittes | T. +49 9771 65-12210 | norman.dittes@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Corporate Communications
Heike Ochmann | T. +49 9771 65-12130 | heike.ochmann@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale

 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. With Campus Bad Neustadt, Zentralklinik
Bad Berka, Klinikum Frankfurt (Oder) as well as the Giessen and Marburg University Hospitals (UKGM), the company has
five highly specialised maximum- and intermediate-care hospitals. As a modern, diverse and future-oriented company,
RHÖN-KLINIKUM AG is attractive both as an employer and training centre. With over 19,100 employees, the Group offers excellent medical care with a direct tie-in to research and teaching. Each year, over 938,000 patients are treated in the
Group’s hospitals and medical care centres (MVZs) on an outpatient and inpatient basis. RHÖN-KLINIKUM AG is a company
of the ASKLEPIOS Group. www.rhoen-klinikum-ag.com



07.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate BSX
EQS News ID: 2323556

 
End of News EQS News Service

2323556  07.05.2026 CET/CEST

Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL. 

Die wichtigsten Finanzdaten auf einen Blick
  2020 2021 2022 2023 2024 2025 2026e
Umsatzerlöse1 1.360,16 1.402,01 1.446,09 1.463,98 1.595,62 1.704,72 1.700,00
EBITDA1,2 80,23 101,16 105,65 105,88 110,77 105,94 117,00
EBITDA-Marge3 5,90 7,22 7,31 7,23 6,94 6,22 6,88
EBIT1,4 10,60 30,52 36,11 40,40 48,15 40,94 44,00
EBIT-Marge5 0,78 2,18 2,50 2,76 3,02 2,40 2,59
Jahresüberschuss1 2,46 30,23 26,94 40,17 45,21 36,28 40,00
Netto-Marge6 0,18 2,16 1,86 2,74 2,83 2,13 2,35
Cashflow1,7 113,30 97,50 41,30 109,00 127,60 57,20 85,00
Ergebnis je Aktie8 0,02 0,42 0,38 0,58 0,65 0,52 0,60
Dividende8 0,00 0,00 0,15 0,00 0,10 0,20 0,20
Quelle: boersengefluester.de und Firmenangaben
Legende

1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.

INVESTOR-INFORMATIONEN
©boersengefluester.de
Rhön-Klinikum
WKN ISIN Rechtsform Börsenwert IPO Einschätzung Plus Code
704230 DE0007042301 AG 837,03 Mio € 19.06.1991 Halten 9F2G86FM+GX
* * *
KGV 2027e KGV 10Y-Ø BGFL-Ratio Shiller-KGV KBV KCV KUV
18,94 26,94 0,70 24,61 -0,47 14,63 0,49
Dividenden
Dividende '2023
in €
Dividende '2024
in €
Dividende '2025e
in €
Div.-Rendite '2025e
in %
0,00 0,10 0,20 1,60%
Finanztermine
Hauptversammlung Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
27.05.2026 07.05.2026 06.08.2026 05.11.2026 26.03.2026
Performance-Angaben
Abstand 60-Tage-Linie Abstand 200-Tage-Linie Performance YtD Kursveränderung 52 Wochen IPO
Akt. Kurs (EoD)
-0,79%
12,50 €
ATH 32,12 €
-0,68% +1,12% -1,57% -3,10% +400,00%

Werbung ist für uns ein wichtiger Einnahmekanal. Aber wir verstehen, dass sie manchmal lästig wird. Wenn Sie die Anzahl der angezeigten Werbung reduzieren möchten, loggen Sie sich einfach in Ihr Benutzerkonto ein und verwalten Sie die Einstellungen von dort aus. Als registrierter Benutzer erhalten Sie viele Vorteile.
          Qualitätsjournalismus · 2013-2026 · Made in Germany          
Die Analyse-Manufaktur

Informierte Anleger treffen bessere Entscheidungen

Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.

Kontakt

Idee & Konzept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2026 von Gereon Kruse #BGFL